Navigation Links
BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients
Date:4/26/2008

eroconversion compared with 25 percent (n=5/20) adefovir-treated

patients.

-- Six BARACLUDE(R) (entecavir)-treated patients and 16 adefovir-treated

patients discontinued therapy prior to week 96.

- No BARACLUDE-treated patients and one adefovir-treated patient

discontinued due to adverse events.

- No BARACLUDE-treated patients and six adefovir-treated patients

discontinued due to investigator-determined treatment failure or lack

of efficacy.

- Three BARACLUDE-treated patients and four adefovir-treated patients

met the treatment response criteria at 52 weeks and entered a 24- or

48-week off-treatment follow-up monitoring phase.

- Two BARACLUDE-treated patients and one adefovir-treated patient were

lost to follow-up, one BARACLUDE-treated patient was non-compliant,

two adefovir-treated patients withdrew consent, one adefovir-treated

patient became pregnant, and one adefovir-randomized patient was

treated with BARACLUDE.

Week 12 (primary endpoint)

-- BARACLUDE-treated patients achieved a mean change in viral load of

-6.23 log(10) copies/mL from baseline, compared to adefovir-treated

patients who achieved a mean change of -4.42 log(10) copies/mL

(p < 0.0001).

-- 12 percent of BARACLUDE-treated patients and 9 percent of

adefovir-treated patients had undetectable viral load (HBV DNA <300

copies/mL).

Additional Cumulative Safety Results of the E.A.R.L.Y. Study at 96 Weeks

-- 83 percent of patients in the BARACLUDE arm (n=30) and 82 percent of

patients in the adefovir arm (n=27) experienced any adverse event.

-- Eight percent of patients receiving BARACLUDE (n=3) and 15 percent of

patients receiving adefovir (n=5) experienced any Grade 3-4 adverse

event.

-- Three percent of patients receiving BARACLU
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients
2. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
3. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
6. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
9. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
10. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
11. Many Heart Attack Patients Dont Get Best Emergency Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2008)...tage A of Trial Assessing Regimen of Bavituxima..., TUSTIN, Calif., Oct. 7 /..., a clinical stage biopharmaceutical,company devel...ancer and,hepatitis C virus (HCV) infection, today... first stage of a Phase II trial of bavituximab in...
(Date:10/6/2008)...ollege of Gastroenterology Annual ...Newswire/ -- Combined results from two Phase 3,stu...terology Annual,Scientific Meeting (ACG) in Orland...igher healing rates than lansoprazole among patien...(EE). TAK-390MR combines,dexlansoprazole with a Du...
(Date:10/6/2008)...te to Improve Patient Safety, WASHINGTON, Oct. 6 ...,Cardiology in collaboration with the American Col...sociation today released consensus guidelines,outl... ulcers and,gastrointestinal (GI) bleeding among p... (NSAIDs) along with antiplatelet agents., Gastro...
(Date:10/6/2008).... 6 /- Complete,Genomics Inc., a newl...ng,company, and the Institute for Systems Biology ... populationwide human genome studies., In phase o...proprietary,DNA sequencing technology to sequence ...nce proof-of-concept has been demonstrated, ISB an...
Breaking Medicine Technology:Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 2Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 3Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 4Takeda's Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed 2Takeda's Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed 3Consensus Document Outlines Practical Steps for Reducing Gastrointestinal Risks of Antiplatelet and NSAID Use 2Consensus Document Outlines Practical Steps for Reducing Gastrointestinal Risks of Antiplatelet and NSAID Use 3Consensus Document Outlines Practical Steps for Reducing Gastrointestinal Risks of Antiplatelet and NSAID Use 4Complete Genomics and the Institute for Systems Biology Announce Partnership to Conduct the First Human Genome Population Study 2125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative 4101 1125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative 4101 2125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative 4101 3125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative 4101 4Pharmacopeia to Present at the 15TH Annual Future Leaders in the Biotech Industry Conference 4097 1Pharmacopeia to Present at the 15TH Annual Future Leaders in the Biotech Industry Conference 4097 2Pharmacopeia to Present at the 15TH Annual Future Leaders in the Biotech Industry Conference 4097 3Pharmacopeia to Present at the 15TH Annual Future Leaders in the Biotech Industry Conference 4097 4New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly 1567 1New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly 1567 2New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly 1567 3New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly 1567 4New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly 1567 5New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly 1567 6New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly 1567 7LUMEDX Updates Real Time Patient and Resource Scheduler for Healthcare Systems 4095 1LUMEDX Updates Real Time Patient and Resource Scheduler for Healthcare Systems 4095 2
... CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 18, 2007 -...ompany focused on,the discovery and development of... findings from its novel human-in-mouse (HIM) tiss...uccessfully created,invasive human tumors that dev...issue. This model enables scientists, for the firs...
...INESS WIRE)--Apr 19, 2007 - Antares Pharma, Inc.,(...tly completed,site application study demonstrating...mal gel, was absorbed on a bioequivalent,basis aft...in site,locations., The study was an open-label, c...harmacokinetic study. The trial enrolled 25,health...
Other Medicine Technology:Novel Human Tissue Transgenic Cancer Model May Offer Significant,Advance Toward Accurately Modeling Human Cancer 2Novel Human Tissue Transgenic Cancer Model May Offer Significant,Advance Toward Accurately Modeling Human Cancer 3Antares Pharma Announces Positive Results from Application Site,Study for Anturol 2Antares Pharma Announces Positive Results from Application Site,Study for Anturol 3
(Date:10/6/2008)... WASHINGTON, Oct. 6 /PRNewswire-USNewswire/ -- ...nst several companies alleging that they,submitted...kbacks and the,establishment of sham durable medic...nt announced today. The companies are McKesson Cor...MediNet), GGNSC Holdings LLC,Golden Gate Ancillar...
(Date:10/6/2008)... A study led by researchers at the University of ...that use of oral Vitamin D supplements bolsters pr...n the skin, and may help prevent skin infections t...most common form of eczema. , The study led by ...and chief of the Division of Dermatology at the UC...
(Date:10/6/2008)... SAN DIEGO, Oct. 6 /PRNewswire/ -- Developed in... of Pacific Palisades, CA is introducing,Revolutio...y into the,Plastic Surgery office of Dr. Steve Lav... XS-300(TM), is the first of its kind, and is base...hnology combined with,innovative proprietary softw...
(Date:10/6/2008)... Vision Audio Inc. has an...deo game designed to help train children with auti...Se Off-Road is a fun, non-violent learning experie...participate in their enhanced sound-based therapy,...dio ( http://www.easecd.com ). , ...
Breaking Medicine News(10 mins):Health News:U.S. Intervenes in False Claims Act Suit Against McKesson Corp. and Golden Horizons Nursing Homes 2Health News:Oral vitamin D may help prevent some skin infections 2Health News:Plan Your Breasts in 3-D 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 3
... the common cold remains as elusive as ever. A fed...the first drug aimed at treating the cause of the ...ed. In a unanimous decision, the Food and Drug Ad...l drugs said there were too many questions about t...
...hemists at the University of north Carolina at Ch... organisms convert genetic instructions into actio...unknown chemical site on a key enzyme that regulat...er known as RNA. When the chemical site is occupie...
...re right if they are feeling bombarded by commerci...ople instead of doctors tripled in the U.S. betwee...ertisements targeting consumers account for 15% of... up from almost 9% in 1996.// Spending that target...
...roup has petitioned the Food and Drug Administrati...Public Citizen says the drug, sold as Meridia, is ...diovascular causes such as heart attacks. But obes...ople died because of Meridia or because they were ...
Other Medicine News:
Since 1991 Intersurgical Incorporated manufactures high efficiency breathing filters, heat and moisture exchangers, ventilator circuits, oxygen therapy products, hand-held nebulizers and an extensive
...right product for any patient ranging from pediatr...nts with tracheotomies. These products offer super...l care applications., ,The Unti-Mist HME and HME/...d staff members. This entire product line of unti-...
Combination heat and moisture exchanger and bacterial/viral filters for Anesthesia and Respiratory applications.
Indications For Usage: ,Adult (recommended tidal volume >150ml), single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended to
Medicine Products: